NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Cartesian Therapeutics, Inc. RNAC
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$400,000
▼ 99.0% vs FY2024
EPS · FY25
$-5.02
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-32575.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 400,000.00
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 32576 cents on every revenue dollar this year.
Per share
USD -5.02
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-35851.2%
Net margin-32575.5%
Return on assets-35.6%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−52.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−84.7%
−52.5%
−23.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 296.4M
total assets, end of FY2025
Total assetsUSD 296.4M
EquityUSD -126.2M
CashUSD 125.1M
Current ratio8.65×
Equity funds -43% of total assets.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.0
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.0
−0.1
0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.0
−0.1
0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
·
·
·
·
·
Net income $B
−0.1
−0.1
−0.2
0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−5.02
−4.49
−49.76
0.10
−0.22
−0.68
−1.22
−2.92
−3.20
−3.89
−15.13
−7.84
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
60.8
−1137.9
·
−3716.0
−281.6
−122.4
·
·
·
Shares out B
0.03
0.03
0.01
0.15
0.12
0.11
0.09
0.02
·
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
32 of 32
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed